New Zealand’s drug regulatory authority, Medsafe, has canceled the registration of 200- and 400-mg tablets of the Cox-2 inhibitor Prexige after reviewing local and international reports of severe liver damage in patients taking high doses of the drug.
The move comes just over a week after Australia’s Therapeutic Goods Administration (TGA) withdrew Novartis’ pain killer altogether. The TGA’s decision was in response to eight serious reactions, including two deaths and two liver transplants.
The 100-mg Prexige (lumiracoxib) tablet remains on the market in New Zealand. The drug is used for the management of osteoarthritis.
Source: http://www.medsafe.govt.nz/hot/media/2007/Prexige.asp
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment